Dr. Robyn J. Barst to Lead Pulmonary Hypertension Clinical Development Program for Validation of the VentriPoint VMS(TM) Heart Analysis System
Guardado en:
| Publicado en: | Marketwire (Jul 11, 2011), p. n/a |
|---|---|
| Autor principal: | |
| Publicado: |
Intrado Digital Media Canada Inc.
|
| Materias: | |
| Acceso en línea: | Citation/Abstract Full Text |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Resumen: | FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize. "We are most fortunate to have Dr. [Robyn J. Barst] as the overall Program Director for our PH program. She is a recognized expert in clinical PH development studies and has the respect of the entire PH community," stated Dr. George Adams, CEO of VentriPoint. "PH is a $1B opportunity where 2D ultrasound and VMS(TM) can become the 'standard of care' in this growing patient population." |
|---|---|
| Fuente: | Canadian Business & Current Affairs Database |